Skip to main content

TUBERCULOSIS: DESARROLLO DE NUEVOS METODOS DIAGNOSTICOS, NUEVAS TERAPIAS DIRIGIDAS AL HUESPED Y UNA MEJOR COMPRENSION DEL IMPACTO DE LOS FACTORES EXTRINSECOS EN LA MODULACION DE LA INFLAMACION. INNOVA-2

PI19/01408

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis

  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Latorre, Irene|||0000-0001-8159-2455
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Martínez-Planas, Aina
  • Minguell Domingo, Laura
  • Vallmanya, Teresa
  • Méndez Hernández, Maria|||0000-0001-5697-2763
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Baquero-Artigao, Fernando|||0000-0002-6903-3826
  • Rodríguez-Molino, Paula
  • Guillén-Martín, Sara
  • Toro Rueda, Carlos
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez-Fuentes, María Ángeles|||0000-0001-5181-4192
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Sabriá, Josefina
  • Santos, José Ramón|||0000-0002-0886-7114
  • Puig, Jordi|||0000-0002-4075-0346
  • Domínguez-Álvarez, Marisol
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Altet, Neus
  • Galea, Yolanda
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • García-García, Esther
  • Bach Griera, Marc|||0000-0001-9845-7225
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Julián, Esther|||0000-0002-6558-3978
  • Torrelles, Jordi B.|||0000-0001-7702-5941
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Domínguez, José|||0000-0001-7888-0309
Background: Diagnosis of nontuberculous mycobacteria (NTM) infections remains a challenge. In this study, we describe the evaluation of an immunological NTM-interferon (IFN)-γ release assay (IGRA) that we developed using glycopeptidolipids (GPLs) as NTM-specific antigens. Methods: We tested the NTM-IGRA in 99 samples from pediatric patients. Seventy-five were patients with lymphadenitis: 25 were NTM confirmed, 45 were of unknown etiology but compatible with mycobacterial infection and 5 had lymphadenitis caused by an etiologic agent other than NTM. The remaining 24 samples were from control individuals without lymphadenitis (latently infected with M.Tuberculosis, uninfected controls and active tuberculosis patients). Peripheral blood mononuclear cells were stimulated overnight with GPLs. Detection of IFN-γ producing cells was evaluated by enzyme-linked immunospot assay. Results: NTM culture-confirmed lymphadenitis patient samples had a significantly higher response to GPLs than the patients with lymphadenitis of unknown etiology but compatible with mycobacterial infection (P < 0.001) and lymphadenitis not caused by NTM (P < 0.01). We analyzed the response against GPLs in samples from unknown etiology lymphadenitis but compatible with mycobacterial infection cases according to the tuberculin skin test (TST) response, and although not statistically significant, those with a TST ≥5 mm had a higher response to GPLs when compared with the TST <5 mm group. Conclusions: Stimulation with GPLs yielded promising results in detecting NTM infection in pediatric patients with lymphadenitis. Our results indicate that the test could be useful to guide the diagnosis of pediatric lymphadenitis. This new NTM-IGRA could improve the clinical handling of NTM-infected patients and avoid unnecessary misdiagnosis and treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MptpB Inhibitor Improves the Action of Antibiotics against Mycobacterium tuberculosis and Nontuberculous Mycobacterium avium Infections

  • Rodríguez-Fernández, Pablo|||0000-0003-1273-0548
  • Botella, Laure
  • Cavet, Jennifer S.
  • Domínguez, José|||0000-0001-7888-0309
  • Gutierrez, Maximiliano G.|||0000-0003-3199-0337
  • Suckling, Colin J.
  • Scott, Fraser J.|||0000-0003-0229-3698
  • Tabernero, Lydia|||0000-0001-8867-455X
Treatment of Mycobacterium tuberculosis and Mycobacterium avium infections requires multiple drugs for long time periods. Mycobacterium protein-tyrosine-phosphatase B (MptpB) is a key M. tuberculosis virulence factor that subverts host antimicrobial activity to promote intracellular survival. Inhibition of MptpB reduces the infection burden in vivo and offers new opportunities to improve current treatments. Here, we demonstrate that M. avium produces an MptpB orthologue and that the MptpB inhibitor C13 reduces the M. avium infection burden in macrophages. Combining C13 with the antibiotics rifampicin or bedaquiline showed an additive effect, reducing intracellular infection of both M. tuberculosis and M. avium by 50%, compared to monotreatment with antibiotics alone. This additive effect was not observed with pretomanid. Combining C13 with the minor groove-binding compounds S-MGB-362 and S-MGB-363 also reduced the M. tuberculosis intracellular burden. Similar additive effects of C13 and antibiotics were confirmed in vivo using Galleria mellonella infections. We demonstrate that the reduced mycobacterial burden in macrophages observed with C13 treatments is due to the increased trafficking to lysosomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis, data from the prospective INNOVA4TB cohort study in Ukraine

  • Dudnyk, Andrii|||0000-0002-8780-9480
  • Hempel, M.
  • Lytvyniuk, O.
  • Liudkevych, H.
  • Matsera, V.
  • Nikitchenko, T.
  • Blyzniuk, S.
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Preyer, R.
  • Domínguez, José|||0000-0001-7888-0309
Background: Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases - 5.4 times more (751) than all 30 European Union/ European Economic Area countries together. Objectives: The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens. Design: A prospective observational cohort study. Methods: From May 2019 to June 2020, we consecutively enrolled patients with active TB hospitalized at the Regional Phthisiopulmonology Center (Vinnytsia, Ukraine), aged between 18 and 82 years. The LPA was performed in the Genetic Research Laboratory at National Pirogov Memorial Medical University, Vinnytsia, Ukraine. Results: A total of 84 clinical specimens and 97 culture isolates from 126 TB patients were tested during the study. Accuracy (95% confidence interval) of LPA for clinical samples in comparison with phenotypic drug susceptibility test (DST) was 80.1 (68.5-89.0) for isoniazid (H), 74.7 (62.4-84.6) for rifampicin (R), 74.4 (62.5-84.1) for ethambutol, 71.4 (41.9-91.6) for streptomycin, 84.6 (62.4-96.5) for prothionamide/ethionamide, and 84.6 (73.6-92.3) for levofloxacin (Lfx), respectively. We found a significantly higher sensitivity of LPA for H, R, and Lfx for the culture isolates compared to clinical specimens (p < 0.05). LPA detected different mutations in 6 out of 17 (35.5%) patients susceptible to R by Xpert. A shorter treatment regimen with an injectable agent demonstrated a low suitability rate of 5% (8/156) in a cohort of RR-TB patients from Ukraine. Conclusion: Initial LPA testing accurately identifies resistance to anti-TB drugs and facilitates the selection of an appropriate treatment regimen, minimizing exposure to empirical therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Benchtop NMR urine metabolomics for diagnosing pulmonary tuberculosis

  • Comella-del-Barrio, Patricia|||0000-0002-2433-9864
  • Rodríguez, Ignacio
  • Bimba, John|||0000-0001-7847-4271
  • Osazuwa, Okoedoh
  • Alaran, Ramota
  • Alonso, Pilar
  • Blasco Iturri, Zuriñe
  • Miguel-Coello, Ana B
  • Cuevas, Luis E.|||0000-0002-6581-0587
  • Ruiz-Cabello, Jesús|||0000-0001-8681-5056
  • Izquierdo-Garcia, José Luis
  • Domínguez, José|||0000-0001-7888-0309
Tuberculosis (TB) remains a major global health issue, especially in resource-limited settings, where rapid and accurate diagnosis is critical yet often lacking. Nuclear magnetic resonance (NMR)-based metabolomics has emerged as a promising tool for identifying disease-specific biomarkers. This study assessed the diagnostic potential of urinary metabolomics using high-resolution (HR-)NMR and benchtop NMR (bNMR) in Nigerian adults with presumed pulmonary TB, including individuals with and without HIV. Urine samples were analysed by HR-NMR and bNMR. Multivariate analysis was used to develop classification models based on confirmed TB status. Key discriminant metabolites were identified. In HIV-negative individuals, HR-NMR achieved 84% sensitivity and 86% specificity, while bNMR reached 83% and 84%, respectively. In people living with HIV, HR-NMR reached 75% sensitivity and 70% specificity; bNMR achieved 90% and 46%. Both models met or exceeded WHO sensitivity criteria for non-sputum-based TB diagnostics. Thirteen discriminatory metabolites were identified, with eight consistent with previous studies. These findings suggest common metabolic signatures of TB, regardless of HIV status. Urinary NMR-based metabolomics shows strong potential for TB diagnosis in high TB/HIV burden settings. HR-NMR provides excellent accuracy, while bNMR offers a cost-effective alternative. Further studies are needed to validate and optimise this approach for clinical use.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment

  • Díaz-Fernández, Sergio
  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Fernández, Marco A.|||0000-0002-3921-2209
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Tolosa, Guillermo
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Jiménez-Fuentes, María Ángeles|||0000-0001-5181-4192
  • Safont Gonzalez, Guillem|||0000-0001-8174-4279
  • Romero i Andrada, Iris
  • Sabrià, Josefina
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Domínguez, José|||0000-0001-7888-0309
  • Latorre, Irene|||0000-0001-8159-2455
Current blood-based diagnostic tools for TB are insufficient to properly characterize the distinct stages of TB, from the latent infection (LTBI) to its active form (aTB); nor can they assess treatment efficacy. Several immune cell biomarkers have been proposed as potential candidates for the development of improved diagnostic tools. To compare the capacity of CD27, HLA-DR, CD38 and Ki-67 markers to characterize LTBI, active TB and patients who ended treatment and resolved TB. Blood was collected from 45 patients defined according to clinical and microbiological criteria as: LTBI, aTB with less than 1 month of treatment and aTB after completing treatment. Peripheral blood mononuclear cells were stimulated with ESAT-6/CFP-10 or PPD antigens and acquired for flow cytometry after labelling with conjugated antibodies against CD3, CD4, CD8, CD27, IFN-γ, TNF-α, CD38, HLA-DR, and Ki-67. Conventional and multiparametric analyses were done with FlowJo and OMIQ, respectively. The expression of CD27, CD38, HLA-DR and Ki-67 markers was analyzed in CD4 + T-cells producing IFN-γ and/or TNF-α cytokines after ESAT-6/CFP-10 or PPD stimulation. Within antigen-responsive CD4 + T-cells, CD27 - and CD38 + (ESAT-6/CFP-10-specific), and HLA-DR + and Ki-67 + (PPD- and ESAT-6/CFP-10-specific) populations were significantly increased in aTB compared to LTBI. Ki-67 demonstrated the best discriminative performance as evaluated by ROC analyses (AUC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Advances in diagnostic tools for respiratory tract infections, from tuberculosis to COVID-19 - changing paradigms?

  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Gonçalves-Carvalho, Filipe|||0000-0003-0665-1667
  • Marín, Alicia|||0000-0002-9358-2120
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Domínguez, José|||0000-0001-7888-0309
  • Latorre, Irene|||0000-0001-8159-2455
  • Lacoma, Alicia|||0000-0002-2049-3872
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
Respiratory tract infections (RTIs) are one of the most common reasons for seeking healthcare, but are amongst the most challenging diseases in terms of clinical decision-making. Proper and timely diagnosis is critical in order to optimise management and prevent further emergence of antimicrobial resistance by misuse or overuse of antibiotics. Diagnostic tools for RTIs include those involving syndromic and aetiological diagnosis: from clinical and radiological features to laboratory methods targeting both pathogen detection and host biomarkers, as well as their combinations in terms of clinical algorithms. They also include tools for predicting severity and monitoring treatment response. Unprecedented milestones have been achieved in the context of the COVID-19 pandemic, involving the most recent applications of diagnostic technologies both at genotypic and phenotypic level, which have changed paradigms in infectious respiratory diseases in terms of why, how and where diagnostics are performed. The aim of this review is to discuss advances in diagnostic tools that impact clinical decision-making, surveillance and follow-up of RTIs and tuberculosis. If properly harnessed, recent advances in diagnostic technologies, including omics and digital transformation, emerge as an unprecedented opportunity to tackle ongoing and future epidemics while handling antimicrobial resistance from a One Health perspective. Unprecedented advances have been achieved by improving and applying the latest technologies to key aspects such as epidemiology, contact tracing and diagnostics of respiratory tract infections that need to be properly addressed for global improvements.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of diesel exhaust particles on infections with Mycobacterium bovis BCG in in vitro human macrophages and an in vivo Galleria mellonella model

  • Rodríguez-Fernández, Pablo|||0000-0003-1273-0548
  • Romero i Andrada, Iris
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Latorre, Irene|||0000-0001-8159-2455
  • Lacoma, Alicia|||0000-0002-2049-3872
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Tabernero, Lydia|||0000-0001-8867-455X
  • Domínguez, José|||0000-0001-7888-0309
There are strong suggestions for a link between pulmonary tuberculosis (TB) and air quality. Diesel exhaust is one of the main contributors to pollution and it is reported to be able to modify susceptibility to lung infections. In this study we exposed THP-1 human macrophages and Mycobacterium bovis BCG to diesel exhaust particles (DEPs). High cytotoxicity and activation of apoptosis was found in THP-1 cells at 3 and 6 days, but no effect was found on the growth of M. bovis BCG. Infection of THP-1 cells exposed to a non-cytotoxic DEP concentration showed a limited capacity to engulf latex beads. However, M. bovis BCG infection of macrophages did not result in an increase in the bacterial burden, but it did result in an increase in the bacteria recovered from the extracellular media, suggesting a poor contention of M. bovis BCG. We also observed that DEP exposure limited the production of cytokines. Using the Galleria mellonella model of infection, we observed that larvae exposed to low levels of DEPs were less able to survive after infection with M. bovis BCG and had a higher internal bacterial load after 4 days of infection. Unraveling the links between air pollution and impairment of human antimycobacterial immunity is vital, because pollution is rapidly increasing in areas where TB incidence is extremely high.